Axitinib, a kinase inhibitor, received approval for the treatment of advanced renal cell cancer and is the seventh drug approved for metastatic or advanced kidney cell cancer since 2005, the Food and Drug Administration announced on Jan. 27."Collectively, this unprecedented level of drug development within this time period has significantly altered the treatment paradigm of metastatic kidney cancer, and offers patients multiple treatment options," Dr. Richard Pazdur, director of the FDA's Office...